AstraZeneca (AZ) has shared positive results from a phase 3b study of its anti-inflammatory reliever rescue therapy Airsupra ...

AstraZeneca presented data from the phase 3 BATURA study which showed that use of Airsupra in those with mild asthma reduced ...

They're produced by an industry-leading manufacturer, but one U.S. agency warns of a defect concerning this well known ...

Results from the pivotal BATURA trial show that Airsupra (albuterol/budesonide) significantly outperformed albuterol ...

AstraZeneca PLC (NASDAQ:AZN), a pharmaceutical and biotech firm based in Cambridge, UK, reported positive results from its ...

Remote study conducted at Rutgers and elsewhere finds albuterol-budesonide mix cuts risk for mild cases and may let patients ...

AstraZeneca recently announced that its AIRSUPRA therapy significantly reduced severe asthma exacerbations, generating strong interest within the medical community. Over the last month ...

The BATURA trial compared the use of Airsupra to albuterol, a commonly used rescue medicine in the US. The trial showed that ...

AstraZeneca (AZN) says “positive” full results from the BATURA Phase IIIb trial showed the company’s anti-inflammatory reliever rescue therapy, Airsupra, demonstrated statistically significant and ...

The results from the AIRSUPRA BATURA trial add to a wide body of evidence on the value of the anti-inflammatory reliever rescue approach to not only provide immediate relief from symptoms ...

As-needed use of a metered-dose inhaler with albuterol plus budesonide (Airsupra) lowered the risk of severe exacerbations ...

AstraZeneca (LSE:AZN) recently announced that its AIRSUPRA therapy significantly reduced severe asthma exacerbations, ...